We are live on ! Find out more
INO icon

Inovio Pharmaceuticals

227 hedge funds and large institutions have $581M invested in Inovio Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 56 funds opening new positions, 72 increasing their positions, 56 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 40

29% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 56

7% more funds holding

Funds holding: 212227 (+15)

0.13% more ownership

Funds ownership: 3.1%3.24% (+0.13%)

16% less call options, than puts

Call options by funds: $45.5M | Put options by funds: $54.1M

20% less capital invested

Capital invested by funds: $723M → $581M (-$142M)

Holders
227
Holders Change
+15
Holders Change %
+7.08%
% of All Funds
4.02%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
56
Increased
72
Reduced
56
Closed
40
Calls
$45.5M
Puts
$54.1M
Net Calls
-$8.6M
Net Calls Change
-$21.8M

INO Hedge Fund Activity: Q4 2020 in Review

227 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q4 2020, worth a combined $581M — down 20% from $723M a quarter earlier.

Buyers outnumbered sellers: 56 funds opened new INO positions and 40 closed out — a net gain of 16 holders — while 72 added to existing stakes and 56 trimmed.

The largest buyer was State Street, adding an estimated $9.91M. The largest seller was Bank of America, cutting an estimated $11.2M.

  • 227 institutional investors held Inovio Pharmaceuticals (INO) as of Q4 2020, up from 212 in Q3 2020.
  • Funds reported $581M of Inovio Pharmaceuticals stock for Q4 2020, down 20% quarter-over-quarter.
  • 56 funds opened new Inovio Pharmaceuticals positions in Q4 2020 and 40 closed out, a net change of +16 holders.
  • The largest Inovio Pharmaceuticals buyer in Q4 2020 was State Street, an estimated $9.91M added.
  • The largest Inovio Pharmaceuticals seller in Q4 2020 was Bank of America, an estimated $11.2M sold.

Based on aggregated 13F filings for Q4 2020.